Literature DB >> 24446034

Correlation of metabolic tumor volume and 11C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images.

Tomohiro Yoneyama1, Ukihide Tateishi, Takashi Terauchi, Tomio Inoue.   

Abstract

PURPOSE: This study was conducted to assess the relationship between (11)C-choline uptake and pathologic findings obtained by combined use of magnetic resonance (MR) and positron emission tomography (PET) imaging of patients with prostate cancer.
MATERIALS AND METHODS: We retrospectively evaluated 69 patients with prostate cancer who underwent (11)C-choline PET-CT and magnetic resonance imaging before radical prostatectomy. Combined MR-PET images were acquired to obtain precise anatomic information. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were compared with pathologic findings from resected specimens as the reference standard.
RESULTS: The mean and standard deviation of tumor SUVmax and MTV were 3.9 ± 1.8 and 12.9 ± 16.4, respectively. Tumors with high MTV (≧8.2) were more likely to be admixed with prostatic intraepithelial neoplasia (PIN) (p < 0.0001) or hyperplasia (p < 0.0001) in the background than those without these findings. Multiple regression analysis also revealed that the presence of hyperplasia (OR; 4.25, 95% CI 1.25-14.4, p = 0.02) and PIN (OR; 9.22, 95% CI 2.60-32.7, p = 0.001) were associated with tumors with high MTV.
CONCLUSION: We have demonstrated, by pathologic evaluation of patients with prostate cancer, that (11)C-choline uptake volume is greater for prostate cancer admixed with PIN and hyperplasia than that without.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24446034     DOI: 10.1007/s11604-014-0283-3

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  19 in total

1.  The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.

Authors:  Michael Souvatzoglou; Gregor Weirich; Sarah Schwarzenboeck; Tobias Maurer; Tibor Schuster; Ralph Alexander Bundschuh; Matthias Eiber; Ken Herrmann; Hubert Kuebler; Hans Juergen Wester; Heinz Hoefler; Juergen Gschwend; Markus Schwaiger; Uwe Treiber; Bernd Joachim Krause
Journal:  Clin Cancer Res       Date:  2011-04-14       Impact factor: 12.531

2.  11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.

Authors:  Soichiro Yoshida; Kazuaki Nakagomi; Shuichi Goto; Masami Futatsubashi; Tatsuo Torizuka
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

3.  Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.

Authors:  Bernhard Scher; Michael Seitz; Wolfram Albinger; Reinhold Tiling; Michael Scherr; Hans-Christoph Becker; Michael Souvatzogluou; Franz-Josef Gildehaus; Hans-Jürgen Wester; Stefan Dresel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-24       Impact factor: 9.236

4.  Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

Authors:  Igle J de Jong; Jan Pruim; Philip H Elsinga; Willem Vaalburg; Han J Mensink
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

Review 5.  The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis.

Authors:  Martin H Umbehr; Michael Müntener; Thomas Hany; Tullio Sulser; Lucas M Bachmann
Journal:  Eur Urol       Date:  2013-04-19       Impact factor: 20.096

6.  Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging.

Authors:  T Hara; M Yuasa
Journal:  Appl Radiat Isot       Date:  1999-03       Impact factor: 1.513

7.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

8.  Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.

Authors:  David Schilling; Heinz P Schlemmer; Philipp H Wagner; Patrick Böttcher; Axel S Merseburger; Philip Aschoff; Roland Bares; Christa Pfannenberg; Ute Ganswindt; Stefan Corvin; Arnulf Stenzl
Journal:  BJU Int       Date:  2008-04-11       Impact factor: 5.588

9.  Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

Authors:  Claudia Testa; Riccardo Schiavina; Raffaele Lodi; Eugenio Salizzoni; Barbara Corti; Mohsen Farsad; John Kurhanewicz; Fabio Manferrari; Eugenio Brunocilla; Caterina Tonon; Nino Monetti; Paolo Castellucci; Stefano Fanti; Manuela Coe; Walter F Grigioni; Giuseppe Martorana; Romeo Canini; Bruno Barbiroli
Journal:  Radiology       Date:  2007-07-24       Impact factor: 11.105

10.  Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness.

Authors:  Ji Chen; Yong Zhao; Xin Li; Peng Sun; Muwen Wang; Ridong Wang; Xunbo Jin
Journal:  Radiol Oncol       Date:  2012-06-19       Impact factor: 2.991

View more
  4 in total

Review 1.  Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.

Authors:  Ananthakrishnan Sivaraman; Kulthe Ramesh Seetharam Bhat
Journal:  Indian J Surg Oncol       Date:  2017-01-23

2.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

3.  Metabolic Volumetric Parameters in 11C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer.

Authors:  Jing-Ren Tseng; Lan-Yan Yang; Yu-Chun Lin; Chung-Yi Liu; See-Tong Pang; Ji-Hong Hong; Tzu-Chen Yen; Li-Jen Wang
Journal:  Contrast Media Mol Imaging       Date:  2018-11-05       Impact factor: 3.161

Review 4.  Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Authors:  Andreas Dimakakos; Athanasios Armakolas; Michael Koutsilieris
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.